Haruka Oi1, Takashi Okuyama2, Shunya Miyazaki1, Yuko Ono3, Masatoshi Oya1. 1. Department of Surgery, Saitama Medical Center, Dokkyo Medical University, Saitama, Japan. 2. Department of Surgery, Saitama Medical Center, Dokkyo Medical University, Saitama, Japan okuyama615@gmail.com. 3. Department of Pathology, Saitama Medical Center, Dokkyo Medical University, Saitama, Japan.
Abstract
AIM: The aim of the present study was to explore the association between CD133 expression and postoperative relapses in patients with locally advanced rectal cancer (LARC) who received neoadjuvant chemotherapy (NAC). PATIENTS AND METHODS: We retrospectively examined 52 patients with LARC (cT3-4, Nany, M0) who received oxaliplatin-based NAC before surgery. CD133 expression was evaluated using immunohistochemistry and divided into low and high expression groups. RESULTS: High CD133 expression was observed in 22 patients (42.3%). Patients with high CD133 expression had more frequent vessel invasion and relapse than those with low CD133 expression (p=0.013 and p=0.036, respectively). Comparing the low with high CD133 expression groups, the 4-year relapse-free survival rates were 82.2% vs. 46.3% (p=0.009). Multivariate analysis indicated that CD133 expression was an independent risk factor for relapse (HR=3.138; 95%CI=1.046-9.412; p=0.041). CONCLUSION: CD133 expression may be a predictive biomarker for postoperative relapse in patients with LARC who received NAC before surgery. Copyright
AIM: The aim of the present study was to explore the association between CD133 expression and postoperative relapses in patients with locally advanced rectal cancer (LARC) who received neoadjuvant chemotherapy (NAC). PATIENTS AND METHODS: We retrospectively examined 52 patients with LARC (cT3-4, Nany, M0) who received oxaliplatin-based NAC before surgery. CD133 expression was evaluated using immunohistochemistry and divided into low and high expression groups. RESULTS: High CD133 expression was observed in 22 patients (42.3%). Patients with high CD133 expression had more frequent vessel invasion and relapse than those with low CD133 expression (p=0.013 and p=0.036, respectively). Comparing the low with high CD133 expression groups, the 4-year relapse-free survival rates were 82.2% vs. 46.3% (p=0.009). Multivariate analysis indicated that CD133 expression was an independent risk factor for relapse (HR=3.138; 95%CI=1.046-9.412; p=0.041). CONCLUSION:CD133 expression may be a predictive biomarker for postoperative relapse in patients with LARC who received NAC before surgery. Copyright
Authors: Nabila Ansari; Michael J Solomon; Richard J Fisher; John Mackay; Bryan Burmeister; Stephen Ackland; Alexander Heriot; David Joseph; Sue-Anne McLachlan; Bev McClure; Samuel Y Ngan Journal: Ann Surg Date: 2017-05 Impact factor: 12.969
Authors: Thilo Sprenger; Lena-Christin Conradi; Tim Beissbarth; Heiko Ermert; Kia Homayounfar; Peter Middel; Josef Rüschoff; Hendrik A Wolff; Philipp Schüler; B Michael Ghadimi; Claus Rödel; Heinz Becker; Franz Rödel; Torsten Liersch Journal: Cancer Date: 2012-06-26 Impact factor: 6.860
Authors: Chitra Joseph; Maariya Arshad; Sasagu Kurozomi; Maryam Althobiti; Islam M Miligy; Sara Al-Izzi; Michael S Toss; Fang Qin Goh; Simon J Johnston; Stewart G Martin; Ian O Ellis; Nigel P Mongan; Andrew R Green; Emad A Rakha Journal: Breast Cancer Res Treat Date: 2018-12-15 Impact factor: 4.872
Authors: Chee W Ong; Lay G Kim; Hui H Kong; Lai Y Low; Barry Iacopetta; Richie Soong; Manuel Salto-Tellez Journal: Mod Pathol Date: 2010-01-15 Impact factor: 7.842
Authors: Samuel Y Ngan; Bryan Burmeister; Richard J Fisher; Michael Solomon; David Goldstein; David Joseph; Stephen P Ackland; David Schache; Bev McClure; Sue-Anne McLachlan; Joseph McKendrick; Trevor Leong; Cris Hartopeanu; John Zalcberg; John Mackay Journal: J Clin Oncol Date: 2012-09-24 Impact factor: 44.544
Authors: Deborah Schrag; Martin Weiser; Leonard Saltz; Harvey Mamon; Marc Gollub; Ethan Basch; Alan Venook; Qian Shi Journal: Clin Trials Date: 2019-01-28 Impact factor: 2.486
Authors: Martin Loos; Philipp Quentmeier; Tibor Schuster; Ulrich Nitsche; Ralf Gertler; Andreas Keerl; Thomas Kocher; Helmut Friess; Robert Rosenberg Journal: Ann Surg Oncol Date: 2012-12-27 Impact factor: 5.344